ADMA vs VKTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ADMA · ADMA Biologics$13.17 ▼ 1.27%
VKTX · Viking Therapeutics$24.77 ▼ 4.14%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ADMA -28.1%
- VKTX -28.5%
Head to head
| Metric | ADMA | VKTX |
|---|---|---|
| Price | $13.17 | $24.77 |
| Change today | ▼ 1.27% | ▼ 4.14% |
| Market cap | $2.92B | $3.16B |
| Return, 3 months | +37.9% | -25.5% |
| Return, year to date | -27.8% | -29.6% |
| Return, 1 year | -23.3% | -27.7% |
| P/E (TTM) | 17.1 | – |
| P/B | 6.7 | 5.4 |
| P/E percentile vs own 5y | 69th | 81st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5.1% | – |
| Net profit growth (YoY) | +36.9% | -101.8% |
| Gross margin | 68.5% | – |
| Operating margin | 44.9% | – |
| Net margin | 35.1% | – |
| Return on equity | 41.9% | -96.4% |
| Analyst target vs. price | +26.6% | +277.6% |
| Analyst buy share | 67% | 94% |
| RSI (14) | 62 | 41 |
| 30-day volatility | 77.7% | 75.0% |
| Max drawdown, 1 year | -62.7% | -42.5% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VKTX is the largest of the group by market value.
- ADMA has returned the most over the past year.
- VKTX has been the calmest stock over the last 30 days.